IGF-1 LR3 (5mg)

# IGF-1 LR3 (Long R3 Insulin-Like Growth Factor-I)

## SCIENTIFIC OVERVIEW
IGF-1 LR3 is a synthetic 83-amino acid analog of human Insulin-Like Growth Factor-I (IGF-I) with an N-terminal extension of 13 amino acids and a glutamic acid substitution at position 3. This modification significantly reduces binding to IGF-binding proteins (IGFBPs), resulting in extended biological half-life and altered receptor kinetics for research applications.

## RESEARCH APPLICATIONS
Scientific studies have investigated IGF-1 LR3 for:
- IGF-1 receptor (IGF-1R) signaling research
- PI3K/Akt pathway activation studies
- MAPK/ERK signaling mechanism analysis
- Muscle satellite cell proliferation research
- Myoblast differentiation studies
- Protein synthesis pathway analysis
- Glucose uptake and GLUT4 translocation research
- Cell culture growth optimization (serum replacement)
- Tissue engineering scaffold studies
- Apoptosis inhibition mechanism research

## PRODUCT SPECIFICATIONS
- **Purity:** ≥95% (RP-HPLC)
- **Form:** Lyophilized Sterile Powder
- **Sequence:** 83 amino acids (R3 analog)
- **Molecular Weight:** ~9,200 Da
- **Modification:** 13 AA N-terminal extension + Glu³ substitution
- **CAS Number:** 946870-92-4
- **Appearance:** White to off-white powder
- **Storage:** -20°C (freezer), desiccated
- **Reconstitution:** Acetic acid (0.1M) or bacteriostatic water
- **Stability:** 24 months frozen; 30 days at 2-8°C (reconstituted)

## QUALITY CONTROL
✓ RP-HPLC purity ≥95%  
✓ Mass spectrometry confirmation (ESI-MS)  
✓ Amino acid composition analysis  
✓ Peptide content assay  
✓ Endotoxin testing: <1.0 EU/mg  
✓ Bioactivity assay (cell proliferation)  
✓ IGFBP binding reduction verification  
✓ pH: 3.0-4.5 (reconstituted in acidic vehicle)  

## BIOCHEMICAL CHARACTERISTICS
**Half-Life Extension:** Approximately 20-30 hours in research models (vs. 10-12 minutes for native IGF-1)

**IGFBP Binding:** Reduced affinity (~80-90% reduction) allows greater free IGF-1 availability

**Receptor Binding:** Maintains high affinity for IGF-1R with altered kinetics due to structural modification

**Stability:** Enhanced stability in physiological conditions compared to native IGF-1

## RECONSTITUTION GUIDELINES
For optimal stability:
- **Option 1:** 0.1M acetic acid (pH 3-4) - most stable
- **Option 2:** Bacteriostatic water with gentle acidification
- **Concentration:** Typically 0.1-1.0 mg/mL for research use
- **Technique:** Add diluent slowly, swirl gently, avoid foaming

## RESEARCH CONSIDERATIONS
IGF-1 LR3 demonstrates superior performance in cell culture applications due to reduced IGFBP sequestration. Commonly used as serum substitute in stem cell research, myoblast cultures, and tissue engineering protocols.

## SCIENTIFIC REFERENCES
Over 200 published studies have utilized Long R3 IGF-I in research applications including muscle biology, aging research, wound healing, and metabolic studies. Notable use in animal models of muscle wasting and tissue repair.

## STORAGE RECOMMENDATIONS
- **Powder:** -20°C in original sealed vial with desiccant
- **Reconstituted:** 2-8°C for up to 30 days (acidic pH)
- **Aliquots:** Single-use aliquots recommended to avoid freeze-thaw
- **Light:** Protect from direct light exposure

## HANDLING PRECAUTIONS
Requires sterile technique. Work in biosafety cabinet when handling powder. Avoid skin contact. Use appropriate PPE. Dispose according to institutional biohazard protocols.

## FOR RESEARCH PURPOSES ONLY
This product is intended strictly for in-vitro research, cell culture applications, and laboratory animal studies. Not for human consumption or clinical use. Not a pharmaceutical or dietary supplement.

---

**DISCLAIMER:** By purchasing, you certify you are a qualified researcher with appropriate training in peptide handling and biosafety protocols. This compound must be used under institutional oversight and in compliance with all applicable regulations.